Brief: Adamis Announces Review Of Strategic Alternatives

DMK Pharmaceuticals

03/10/2022 21:46

Oct 3 (Reuters) - Adamis Pharmaceuticals Corp  ADMP.O :
    * ADAMIS ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES
    * ADAMIS PHARMACEUTICALS - HAS INITIATED A PROCESS TO
EXPLORE A
RANGE OF STRATEGIC AND FINANCING ALTERNATIVES FOCUSED ON
MAXIMIZING STOCKHOLDER VALUE
    * ADAMIS PHARMACEUTICALS CORP - POTENTIAL ALTERNATIVES
INCLUDE A
PARTNERSHIP OR SALE OF ONE OR BOTH OF CO'S COMMERCIAL PRODUCTS
SYMJEPI AND ZIMHI
    * ADAMIS PHARMACEUTICALS CORP - POTENTIAL ALTERNATIVES
INCLUDE A
MERGER, SALE, OR REVERSE MERGER OF COMPANY, OR/AND SEEKING
ADDITIONAL FINANCING
    * ADAMIS PHARMACEUTICALS CORP - ALSO REVIEWING AND INTENDS
TO
PURSUE EXPENSE REDUCTION ALTERNATIVES AND MEASURES
    * ADAMIS PHARMACEUTICALS - ENGAGED INVESTMENT BANK RAYMOND
JAMES &
ASSOCIATES TO ACT AS STRATEGIC ADVISOR IN EVALUATING CERTAIN
ALTERNATIVES
    * ADAMIS PHARMACEUTICALS CORP - ALTERNATIVE MEASURES MAY
INCLUDE,
WITHOUT LIMITATION, EMPLOYEE HEADCOUNT REDUCTIONS
    * ADAMIS PHARMACEUTICALS CORP - IF COMPANY IS UNABLE TO
COMPLETE A
TRANSACTION, IT MAY BE REQUIRED TO SEEK BANKRUPTCY PROTECTION
    * ADAMIS PHARMA - IF CO IS UNABLE TO COMPLETE A TRANSACTION,
MAY
BE REQUIRED TO SEEK ALTERNATIVES FOR RESTRUCTURING, RESOLVING
LIABILITIES
    * ADAMIS PHARMACEUTICALS - ALTERNATIVE MEASURES WHICH MAY
INCLUDE,
WITHOUT LIMITATION, REDUCTION OR DISCONTINUATION OF CERTAIN
PRODUCT DEVELOPMENT PROGRAMS

Source text for Eikon:  ID:nGNX9mlYDn 
Further company coverage:  ADMP.O 
 ((Reuters.Briefs@thomsonreuters.com;))